Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 1035Neoplasms 813Carcinoma, Non-Small-Cell Lung 796Prostatic Neoplasms 617Colorectal Neoplasms 533Lung Neoplasms 478Neoplasm Metastasis 434Multiple Myeloma 394Leukemia, Myeloid, Acute 380Ovarian Neoplasms 333Pancreatic Neoplasms 316Melanoma 293Squamous Cell Carcinoma of Head and Neck 266Recurrence 260Carcinoma, Hepatocellular 248Glioblastoma 237Brain Neoplasms 236Triple Negative Breast Neoplasms 213Head and Neck Neoplasms 210Carcinoma, Renal Cell 207Precursor Cell Lymphoblastic Leukemia-Lymphoma 203Lymphoma 198Stomach Neoplasms 197Endometrial Neoplasms 190Uterine Cervical Neoplasms 182Lymphoma, Non-Hodgkin 182Sarcoma 180Glioma 179Lymphoma, Large B-Cell, Diffuse 166Hematologic Neoplasms 162

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphomatoid Papulosis × 90 days × Clear all
NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
58 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡